Predictive Utility of Marketed Volumetric Software Tools in Subjects at Risk for Alzheimer Disease: Do Regions Outside the Hippocampus Matter?
Open Access
- 5 January 2017
- journal article
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 38 (3) , 546-552
Abstract
BACKGROUND AND PURPOSE: Alzheimer disease is a prevalent neurodegenerative disease. Computer assessment of brain atrophy patterns can help predict conversion to Alzheimer disease. Our aim was to assess the prognostic efficacy of individual-versus-combined regional volumetrics in 2 commercially available brain volumetric software packages for predicting conversion of patients with mild cognitive impairment to Alzheimer disease. MATERIALS AND METHODS: Data were obtained through the Alzheimer9s Disease Neuroimaging Initiative. One hundred ninety-two subjects (mean age, 74.8 years; 39% female) diagnosed with mild cognitive impairment at baseline were studied. All had T1-weighted MR imaging sequences at baseline and 3-year clinical follow-up. Analysis was performed with NeuroQuant and Neuroreader. Receiver operating characteristic curves assessing the prognostic efficacy of each software package were generated by using a univariable approach using individual regional brain volumes and 2 multivariable approaches (multiple regression and random forest), combining multiple volumes. RESULTS: On univariable analysis of 11 NeuroQuant and 11 Neuroreader regional volumes, hippocampal volume had the highest area under the curve for both software packages (0.69, NeuroQuant; 0.68, Neuroreader) and was not significantly different (P > .05) between packages. Multivariable analysis did not increase the area under the curve for either package (0.63, logistic regression; 0.60, random forest NeuroQuant; 0.65, logistic regression; 0.62, random forest Neuroreader). CONCLUSIONS: Of the multiple regional volume measures available in FDA-cleared brain volumetric software packages, hippocampal volume remains the best single predictor of conversion of mild cognitive impairment to Alzheimer disease at 3-year follow-up. Combining volumetrics did not add additional prognostic efficacy. Therefore, future prognostic studies in mild cognitive impairment, combining such tools with demographic and other biomarker measures, are justified in using hippocampal volume as the only volumetric biomarker.Keywords
This publication has 36 references indexed in Scilit:
- Prediction of MCI to AD conversion, via MRI, CSF biomarkers, and pattern classificationNeurobiology of Aging, 2011
- Predicting MCI outcome with clinically available MRI and CSF biomarkersNeurology, 2011
- Automated detection of brain atrophy patterns based on MRI for the prediction of Alzheimer's diseaseNeuroImage, 2010
- MRI and CSF biomarkers in normal, MCI, and AD subjectsNeurology, 2009
- Baseline and longitudinal patterns of brain atrophy in MCI patients, and their use in prediction of short-term conversion to AD: Results from ADNI☆NeuroImage, 2009
- MRI measures of temporoparietal regions show differential rates of atrophy during prodromal ADNeurology, 2008
- Detection of prodromal Alzheimer's disease via pattern classification of magnetic resonance imagingNeurobiology of Aging, 2008
- Amnestic Mild Cognitive Impairment: Structural MR Imaging Findings Predictive of Conversion to Alzheimer DiseaseAmerican Journal of Neuroradiology, 2008
- MRI-derived entorhinal volume is a good predictor of conversion from MCI to ADNeurobiology of Aging, 2004
- The Problem of OverfittingJournal of Chemical Information and Computer Sciences, 2003